Baidu
map

Nat Commun:多癌风险位点chr5p15.33的功能鉴定阐释了通过ZNF148对TERT的调控机制

2017-04-27 AlexYang MedSci原创

全基因组关联性研究(GWAS)定位了chr5p15.33上的许多独立的癌症敏感位点。最近研究中,研究人员展示了在这些位点中的其中一个(Region 2 in CLPTM1L)上,胰腺癌和睾丸癌GWAS的精细作图并聚焦于九个高度相关的SNPs的信号。在这些位点中,rs36115365-C 与胰腺癌和睾丸癌的增加先关,并且与肺癌和黑色瘤风险的减少有关,还展现了蛋白结合偏好性和增强了的调控活性。研究人员

全基因组关联性研究(GWAS)定位了chr5p15.33上的许多独立的癌症敏感位点。最近研究中,研究人员展示了在这些位点中的其中一个(Region 2 in CLPTM1L)上,胰腺癌和睾丸癌GWAS的精细作图并聚焦于九个高度相关的SNPs的信号。

在这些位点中,rs36115365-C 与胰腺癌和睾丸癌的增加先关,并且与肺癌和黑色瘤风险的减少有关,还展现了蛋白结合偏好性和增强了的调控活性。研究人员还发现,该调控原件的转录基因沉默可以以一个特异性等位基因的方式抑制TERT的表达。另外,蛋白组学分析鉴定了锌指蛋白148(ZNF148)对rs36115365-C的等位偏好性结合,ZNF148的纯化重组结合进一步支持了上述结论。ZNF148的敲除可以导致TERT表达量的减少,并降低端粒酶的活性和减少端粒的长度。最后,研究人员指出,他们的研究表明了chr5p15.33-Region 2与癌症的相关性也许可以由rs36115365来解释,而rs36115365可以通过ZNF148来对TERT的表达产生不同的影响。

原始出处:

Jun Fang, Jinping Jia, Matthew Makowski et al. Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148.Nat Commun. 27 April 2017. doi:10.1038/ncomms15034.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1881970, encodeId=7a9818819e02a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 07 06:00:00 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061613, encodeId=f95e206161353, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Jul 30 23:00:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927977, encodeId=958d192e977a2, content=<a href='/topic/show?id=ed8712e399b' target=_blank style='color:#2F92EE;'>#NF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12739, encryptionId=ed8712e399b, topicName=NF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Wed Mar 14 08:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087007, encodeId=6d72208e00753, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Oct 05 06:00:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=194144, encodeId=5614194144b4, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri May 05 12:40:07 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497613, encodeId=f2e3149e613b5, content=<a href='/topic/show?id=02599201364' target=_blank style='color:#2F92EE;'>#调控机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92013, encryptionId=02599201364, topicName=调控机制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bce9348572, createdName=villahu, createdTime=Sat Apr 29 13:00:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191500, encodeId=7196191500a1, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri Apr 28 15:01:45 CST 2017, time=2017-04-28, status=1, ipAttribution=)]
    2017-11-07 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1881970, encodeId=7a9818819e02a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 07 06:00:00 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061613, encodeId=f95e206161353, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Jul 30 23:00:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927977, encodeId=958d192e977a2, content=<a href='/topic/show?id=ed8712e399b' target=_blank style='color:#2F92EE;'>#NF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12739, encryptionId=ed8712e399b, topicName=NF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Wed Mar 14 08:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087007, encodeId=6d72208e00753, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Oct 05 06:00:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=194144, encodeId=5614194144b4, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri May 05 12:40:07 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497613, encodeId=f2e3149e613b5, content=<a href='/topic/show?id=02599201364' target=_blank style='color:#2F92EE;'>#调控机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92013, encryptionId=02599201364, topicName=调控机制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bce9348572, createdName=villahu, createdTime=Sat Apr 29 13:00:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191500, encodeId=7196191500a1, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri Apr 28 15:01:45 CST 2017, time=2017-04-28, status=1, ipAttribution=)]
    2017-07-30 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=1881970, encodeId=7a9818819e02a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 07 06:00:00 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061613, encodeId=f95e206161353, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Jul 30 23:00:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927977, encodeId=958d192e977a2, content=<a href='/topic/show?id=ed8712e399b' target=_blank style='color:#2F92EE;'>#NF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12739, encryptionId=ed8712e399b, topicName=NF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Wed Mar 14 08:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087007, encodeId=6d72208e00753, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Oct 05 06:00:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=194144, encodeId=5614194144b4, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri May 05 12:40:07 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497613, encodeId=f2e3149e613b5, content=<a href='/topic/show?id=02599201364' target=_blank style='color:#2F92EE;'>#调控机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92013, encryptionId=02599201364, topicName=调控机制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bce9348572, createdName=villahu, createdTime=Sat Apr 29 13:00:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191500, encodeId=7196191500a1, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri Apr 28 15:01:45 CST 2017, time=2017-04-28, status=1, ipAttribution=)]
    2018-03-14 ay2000fy
  4. [GetPortalCommentsPageByObjectIdResponse(id=1881970, encodeId=7a9818819e02a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 07 06:00:00 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061613, encodeId=f95e206161353, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Jul 30 23:00:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927977, encodeId=958d192e977a2, content=<a href='/topic/show?id=ed8712e399b' target=_blank style='color:#2F92EE;'>#NF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12739, encryptionId=ed8712e399b, topicName=NF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Wed Mar 14 08:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087007, encodeId=6d72208e00753, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Oct 05 06:00:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=194144, encodeId=5614194144b4, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri May 05 12:40:07 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497613, encodeId=f2e3149e613b5, content=<a href='/topic/show?id=02599201364' target=_blank style='color:#2F92EE;'>#调控机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92013, encryptionId=02599201364, topicName=调控机制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bce9348572, createdName=villahu, createdTime=Sat Apr 29 13:00:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191500, encodeId=7196191500a1, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri Apr 28 15:01:45 CST 2017, time=2017-04-28, status=1, ipAttribution=)]
    2017-10-05 liuli5079
  5. [GetPortalCommentsPageByObjectIdResponse(id=1881970, encodeId=7a9818819e02a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 07 06:00:00 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061613, encodeId=f95e206161353, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Jul 30 23:00:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927977, encodeId=958d192e977a2, content=<a href='/topic/show?id=ed8712e399b' target=_blank style='color:#2F92EE;'>#NF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12739, encryptionId=ed8712e399b, topicName=NF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Wed Mar 14 08:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087007, encodeId=6d72208e00753, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Oct 05 06:00:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=194144, encodeId=5614194144b4, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri May 05 12:40:07 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497613, encodeId=f2e3149e613b5, content=<a href='/topic/show?id=02599201364' target=_blank style='color:#2F92EE;'>#调控机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92013, encryptionId=02599201364, topicName=调控机制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bce9348572, createdName=villahu, createdTime=Sat Apr 29 13:00:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191500, encodeId=7196191500a1, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri Apr 28 15:01:45 CST 2017, time=2017-04-28, status=1, ipAttribution=)]
    2017-05-05 卡圣

    学习了,谢谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1881970, encodeId=7a9818819e02a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 07 06:00:00 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061613, encodeId=f95e206161353, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Jul 30 23:00:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927977, encodeId=958d192e977a2, content=<a href='/topic/show?id=ed8712e399b' target=_blank style='color:#2F92EE;'>#NF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12739, encryptionId=ed8712e399b, topicName=NF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Wed Mar 14 08:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087007, encodeId=6d72208e00753, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Oct 05 06:00:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=194144, encodeId=5614194144b4, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri May 05 12:40:07 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497613, encodeId=f2e3149e613b5, content=<a href='/topic/show?id=02599201364' target=_blank style='color:#2F92EE;'>#调控机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92013, encryptionId=02599201364, topicName=调控机制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bce9348572, createdName=villahu, createdTime=Sat Apr 29 13:00:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191500, encodeId=7196191500a1, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri Apr 28 15:01:45 CST 2017, time=2017-04-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1881970, encodeId=7a9818819e02a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 07 06:00:00 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061613, encodeId=f95e206161353, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Jul 30 23:00:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927977, encodeId=958d192e977a2, content=<a href='/topic/show?id=ed8712e399b' target=_blank style='color:#2F92EE;'>#NF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12739, encryptionId=ed8712e399b, topicName=NF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Wed Mar 14 08:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087007, encodeId=6d72208e00753, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Oct 05 06:00:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=194144, encodeId=5614194144b4, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri May 05 12:40:07 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497613, encodeId=f2e3149e613b5, content=<a href='/topic/show?id=02599201364' target=_blank style='color:#2F92EE;'>#调控机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92013, encryptionId=02599201364, topicName=调控机制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bce9348572, createdName=villahu, createdTime=Sat Apr 29 13:00:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191500, encodeId=7196191500a1, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri Apr 28 15:01:45 CST 2017, time=2017-04-28, status=1, ipAttribution=)]
    2017-04-28 卡圣

    学习了,谢谢分享

    0

相关资讯

科学家如何深度破解癌症基因组的奥秘?

此前,国际癌症基因组联盟(International Cancer Genome Consortium)向科学界公布了超过1万个癌症基因组的数据,利用这些数据科学家们就能够更好地从基因方面入手来了解癌症的发生及进展机制,这就为后期研究人员开发治疗多种癌症的新型靶向疗法提供了新的思路。 近年来,科学家们一直在深入进行癌症基因组学等相关研究,他们希望通过深入剖析能够鉴别出引发癌症的根本原

PLOS ONE:一些古老的线索揭示癌症难以治愈的原因

宫颈癌复发时往往是致命的,医生想知道一种新的治疗性疫苗是否可以预防或减少高危患者的复发。疫苗正在高风险患者中进行研究,因为有证据表明癌细胞已经扩散到骨盆淋巴结,或者是因为在第一次诊断出这种疾病的时候已经是晚期。该疫苗被相信会引起免疫反应,使女性利用自己的身体更好地摆脱疾病。 佐治亚州格鲁吉亚医学院妇产科肿瘤科主任Sharad A. Ghamande博士和奥古斯塔大学格鲁吉亚癌症中心临床研

癌症,为什么大多一发现就是晚期呢?

最近,综合治疗科来了三名患者,最小的24岁,最大的65岁,另外一位32岁。他们虽年龄各异,性格不同,却有着共同的诊断:胃癌晚期,腹腔转移。在对他们的病史进行进一步了解后,找到了他们的一个共同点,就是:没有病史。 

Nat Nanotechnol:简约型纳米疫苗,助力癌症免疫治疗

日前,Nature子刊《Nature Nanotechnology》在线发表一篇题为“A STING-activating nanovaccine for cancer immunotherapy”的文章,揭示了一种纳米疫苗PC7A NP,成功在多种患癌小鼠体内表现出抗肿瘤功效,有望助力癌症免疫治疗。这一疫苗的亮点在于简约性——minimalist nanovaccine,由聚合纳米颗粒包裹肿瘤抗

缺氧真的是导致癌细胞不断肆虐的元凶?

1955年,研究者Thomlinson等人在对来自肺癌患者的肿瘤组织进行研究时首次提出肿瘤缺氧的观点,随后科学家们经过60多年临床和实验证实,缺氧状态是多种实体瘤中广泛存在的一种特质,而且缺氧这种特征与肿瘤的增殖、分化、血管生成、能量代谢以及癌症的耐药性发生、患者预后较差密切相关。 很多研究人员认为缺氧是癌细胞不断得以繁衍的一个关键因素,而且缺氧还会让肿瘤细胞的恶性程度不断增加,近日

Nature Commun:协助引起各种癌症的“帮凶”——TET2

【科学家找到了刺激癌症形成的催化剂】想象一下这个场景:在高速公路上,司机突然想转向,然后意识到自己的错误,迅速转向,已经来不及了。其他司机们都来不及反应,因此开始发生碰撞。这一场景就好像各种血癌中TET2蛋白质的情况,TET2可以抑制肿瘤,阻止造血干细胞疯涨,然而,如果TET2发生突变,它还会引起其他基因突变,TET2的突变并不会直接致癌,但是却为癌症的形成创造了条件。研究人员表示:“如果你只是失

Baidu
map
Baidu
map
Baidu
map